Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding ...
Star Therapeutics has completed a Series D funding round, raising $125m aimed at supporting its pipeline progression. The ...
Free period products will be offered in public spaces thanks to a woman whose period can last up to 12 days because of a ...
Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...
The recombinant treatment is now approved for prophylactic use in adults and for treating bleeding episodes and perioperative use in children ...
When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Getty Images/ bluecinema Von Willebrand disease in dogs is the most common inherited ...
Vonvendi is now approved for routine prophylaxis to reduce bleeding frequency in adults with all types of VWD (Type 1, 2, and 3). The Food and Drug Administration (FDA) has expanded the approval of ...
DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease (VWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts ...
Findings showed that routine prophylaxis with wilate resulted in an 84% reduction in mean total ABRs compared with on-demand treatment. The Food and Drug Administration (FDA) has expanded the approval ...
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK, TKPHF, 4502.T) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...
DelveInsight’s latest report, “Von Willebrand Disease (VWD) – Market Insight, Epidemiology, and Market Forecast – 2034,” highlights how evolving therapies, regulatory milestones, and competition are ...
A South San Francisco biotech company is taking on pharmaceutical giants with a novel approach to treating a rare blood ...